Stockscreener 앱 받기
6.38
7.77%
0.46
시장 영업 전:
6.44
0.06
+0.94%
전일 마감가:
$5.92
열려 있는:
$6.08
하루 거래량:
29,420
Relative Volume:
0.54
시가총액:
$16.17M
수익:
-
순이익/손실:
$-11.74M
주가수익비율:
-0.6036
EPS:
-10.5698
순현금흐름:
$-9.50M
1주 성능:
-1.54%
1개월 성능:
-10.39%
6개월 성능:
+2.90%
1년 성능:
-87.43%
1일 변동 폭
$5.8379
$6.38
1주일 범위
$5.7895
$6.39
52주 변동 폭
$4.6325
$52.25
인텐시티 테라퓨틱스 Stock (INTS) Company Profile
명칭
Intensity Therapeutics Inc
전화
203-221-7381
주소
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
6.38 | 15.00M | 0 | -11.74M | -9.50M | -10.57 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
인텐시티 테라퓨틱스 주식(INTS)의 최신 뉴스
US Market Recap: Does Intensity Therapeutics Inc have strong EBITDA margins2026 Sector Moves & Verified Momentum Watchlists - baoquankhu1.vn
Intensity Therapeutics receives new US patent for cancer treatment By Investing.com - Investing.com Australia
Intensity Therapeutics issued new patent in the US - TipRanks
Intensity Therapeutics receives new US patent for cancer treatment - Investing.com
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US - ChartMill
Intensity Therapeutics Inc increases ATM offering capacity to $60 million on March 23, 2026SEC filing - marketscreener.com
Intensity Therapeutics IncIncreases ATM Offering Capacity To $60 Million On March 23, 2026SEC Filing - TradingView
Intensity Therapeutics Expands ATM Equity Offering Capacity - TipRanks
Intensity Therapeutics boosts ATM capacity to $60.0M to enhance financing flexibility - TradingView
Intensity Therapeutics (NASDAQ: INTS) boosts $60M at-the-market capacity - Stock Titan
Intensity Therapeutics (NASDAQ: INTS) raises ATM capacity to $60M - Stock Titan
If You Invested $1,000 in INTENSITY THERAPEUTICS INC (INTS) - Stock Titan
Is Intensity Therapeutics Inc currently under institutional pressure2026 Trends & High Win Rate Trade Tips - baoquankhu1.vn
Block Trades: Is Intensity Therapeutics Inc currently under institutional pressureWeekly Market Outlook & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Technical Analysis: Is Intensity Therapeutics Inc stock a top performer YTD2026 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn
Aug Rallies: Should I set a stop loss on Intensity Therapeutics Inc2026 Rallies & Daily Risk Controlled Trade Plans - baoquankhu1.vn
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Forecast Cut: Can Intensity Therapeutics Inc ride the EV waveWeekly Profit Analysis & Technical Entry and Exit Alerts - baoquankhu1.vn
Intensity Therapeutics regains compliance with Nasdaq's minimum bid price requirement - MSN
Intensity Therapeutics reports early trial data in breast cancer - Investing.com Nigeria
Intensity Therapeutics updates breast cancer trial, files to resume enrollment following study pause - MSN
Intensity Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Nigeria
Alliance Global Partners Sticks to Their Buy Rating for Intensity Therapeutics, Inc. (INTS) - The Globe and Mail
Intensity Therapeutics Inc (INTS) Stock Price, Quote, News & History - Benzinga
Intensity Therapeutics price target adjusted to $30 at Alliance Global - TipRanks
Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause - Sahm
Intensity Therapeutics reports early trial data in breast cancer By Investing.com - Investing.com Australia
Intensity Therapeutics provides update on INVINCIBLE-4 Study - TipRanks
Ballard Reports Q4 2025 and Full Year Results - Weekly Voice
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - ChartMill
Bear Alert: Is Intensity Therapeutics Inc likely to announce a buyback2026 Intraday Action & Growth Focused Investment Plans - baoquankhu1.vn
Take Profit: Should I set a stop loss on Intensity Therapeutics Inc2026 Outlook & Safe Entry Point Identification - baoquankhu1.vn
INTS SEC FilingsINTENSITY THERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Intensity Therapeutics Regains Nasdaq Compliance, Stabilizing Market Listing - The Globe and Mail
Investment Review: Can Intensity Therapeutics Inc disrupt its industryQuarterly Earnings Report & Daily Oversold Bounce Ideas - baoquankhu1.vn
What's going on with Intensity Therapeutics stock Friday? - MSN
CT biotech firm regains Nasdaq compliance after carrying out reverse-stock split - Hartford Business Journal
Intensity Therapeutics Regains Nasdaq $1.00 Minimum Bid Price Compliance - TradingView
Intensity Therapeutics regains Nasdaq compliance - TipRanks
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement - PR Newswire
Why Is Retail Going Gaga Over INTS Stocks Today? - Stocktwits
Why Did INTS Stock Plummet 25% Today? - Stocktwits
INTS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Intensity Therapeutics Announces Reverse Stock Split - 富途牛牛
Swing Trade: Whats next for Intensity Therapeutics Inc stockPortfolio Return Summary & Verified Chart Pattern Signals - baoquankhu1.vn
Retail Trends: Is Intensity Therapeutics Inc stock influenced by commodity pricesJuly 2025 Setups & Daily Profit Focused Screening - baoquankhu1.vn
INTS.O Technical Analysis & Stock Price Forecast - Intellectia AI
VTVT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
INTS Should I Buy - Intellectia AI
INTS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
INTS.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
인텐시티 테라퓨틱스 (INTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):